{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:54:09Z","timestamp":1793836449006,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stroke is a significant cause of morbidity and mortality worldwide, with cerebral edema being a major complication. Glibenclamide, a SUR1-TRPM4 channel inhibitor, has been proposed to reduce cerebral edema, but its clinical efficacy remains uncertain. This meta-analysis aimed to evaluate the efficacy and safety of glibenclamide in patients with stroke, including acute ischemic stroke, acute subarachnoid hemorrhage, and intracerebral hemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus up to January 2025. The primary efficacy outcomes included excellent (modified Rankin Scale [mRS] score 0\u20131) and good (mRS score 0\u20132) functional outcomes at 90\u00a0days. Safety outcomes included the incidence of hypoglycemia and decompressive craniectomy. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten and eight randomized controlled trials (RCTs) were included in our qualitative and quantitative analysis, respectively, encompassing 1,691 participants aged 18 to 85. No significant difference was observed between the glibenclamide and control groups regarding excellent functional outcome (risk ratio [RR] 1.10, 95% confidence interval [CI] 0.92\u20131.32,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.29) and good functional outcome (RR 1.07, 95% CI 0.96\u20131.18,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.22). Safety analysis revealed no significant increase in serious adverse events (RR 1.11, 95% CI 1.00\u20131.23,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.06). Notably, hypoglycemia incidence after sensitivity analysis was higher in the glibenclamide group (RR 4.56, 95% CI 2.07\u201310.03,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glibenclamide did not significantly improve functional outcomes or reduce mortality in stroke patients but was associated with a higher incidence of hypoglycemia. Further well-designed RCTs are needed to clarify its therapeutic role and optimize safety protocols.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Clinical trial registration<\/jats:italic>\n                      : PROSPERO registration number: CRD420251008350.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-025-02311-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:16:52Z","timestamp":1752139012000},"page":"1013-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Efficacy and Safety of Glibenclamide in Improving Cerebral Edema and Neurological Outcomes in Stroke: a GRADE-Evaluated Systematic Review and Meta-analysis with Subgroup Analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-8694","authenticated-orcid":false,"given":"Hazem E.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Bady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Meshref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"5","key":"2311_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/svn-2023-002892","volume":"9","author":"X Feng","year":"2024","unstructured":"Feng X, Zhang T, Wang N, et al. Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial. Stroke Vasc Neurol. 2024;9(5):530\u201340.","journal-title":"Stroke Vasc Neurol"},{"issue":"3","key":"2311_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12028-024-01999-z","volume":"41","author":"Q Lin","year":"2024","unstructured":"Lin Q, Zhou D, Ma J, et al. Efficacy and safety of early treatment with glibenclamide in patients with aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Neurocrit Care. 2024;41(3):828\u201339.","journal-title":"Neurocrit Care"},{"issue":"3","key":"2311_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s13311-011-0053-1","volume":"8","author":"B Ovbiagele","year":"2011","unstructured":"Ovbiagele B, Nguyen-Huynh MN. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319\u201329.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2311_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3171\/2021.7.JNS21846","volume":"137","author":"BBS da Costa","year":"2022","unstructured":"da Costa BBS, Windlin IC, Koterba E, et al. Glibenclamide in aneurysmal subarachnoid hemorrhage: a randomized controlled clinical trial. J Neurosurg. 2022;137(1):121\u20138.","journal-title":"J Neurosurg"},{"issue":"9","key":"2311_CR5","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1161\/STROKEAHA.117.018223","volume":"48","author":"M Thor\u00e9n","year":"2017","unstructured":"Thor\u00e9n M, Azevedo E, Dawson J, et al. Predictors for cerebral edema in acute ischemic stroke treated with intravenous thrombolysis. Stroke. 2017;48(9):2464\u201371.","journal-title":"Stroke"},{"key":"2311_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.988283","volume":"16","author":"Y Gu","year":"2022","unstructured":"Gu Y, Zhou C, Piao Z, et al. Cerebral edema after ischemic stroke: Pathophysiology and underlying mechanisms. Front Neurosci. 2022;16: 988283.","journal-title":"Front Neurosci"},{"key":"2311_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106029","volume":"178","author":"W Han","year":"2023","unstructured":"Han W, Song Y, Rocha M, Shi Y. Ischemic brain edema: Emerging cellular mechanisms and therapeutic approaches. Neurobiol Dis. 2023;178: 106029.","journal-title":"Neurobiol Dis"},{"issue":"23","key":"2311_CR8","doi-asserted-by":"publisher","first-page":"e2163","DOI":"10.1212\/WNL.0000000000006618","volume":"91","author":"WT Kimberly","year":"2018","unstructured":"Kimberly WT, Bevers MB, von Kummer R, et al. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. Neurology. 2018;91(23):e2163\u20139.","journal-title":"Neurology"},{"key":"2311_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102305","volume":"65","author":"K Huang","year":"2023","unstructured":"Huang K, Zhao X, Zhao Y, et al. Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion\/stenosis of anterior circulation (SE-GRACE): a randomized, double-blind, placebo-controlled trial. EClinicalMedicine. 2023;65: 102305.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"2311_CR10","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1474-4422(16)30196-X","volume":"15","author":"KN Sheth","year":"2016","unstructured":"Sheth KN, Elm JJ, Molyneaux BJ, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016;15(11):1160\u20139.","journal-title":"Lancet Neurol"},{"issue":"12","key":"2311_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S1474-4422(24)00425-3","volume":"23","author":"KN Sheth","year":"2024","unstructured":"Sheth KN, Albers GW, Saver JL, et al. Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Neurol. 2024;23(12):1205\u201313.","journal-title":"Lancet Neurol"},{"key":"2311_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3171\/jns.1962.19.12.1038","volume":"19","author":"BL Wise","year":"1962","unstructured":"Wise BL, Chater N. The value of hypertonic mannitol solution in decreasing brain mass and lowering cerebro-spinal-fluid pressure. J Neurosurg. 1962;19:1038\u201343.","journal-title":"J Neurosurg"},{"issue":"11","key":"2311_CR13","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1161\/STROKEAHA.107.490193","volume":"38","author":"J Bardutzky","year":"2007","unstructured":"Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke. 2007;38(11):3084\u201394.","journal-title":"Stroke"},{"issue":"1","key":"2311_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/neu.2019.6538","volume":"37","author":"HM Eisenberg","year":"2020","unstructured":"Eisenberg HM, Shenton ME, Pasternak O, et al. Magnetic resonance imaging pilot study of intravenous glyburide in traumatic brain injury. J Neurotrauma. 2020;37(1):185\u201393.","journal-title":"J Neurotrauma"},{"issue":"7","key":"2311_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7): e1000100.","journal-title":"PLoS Med"},{"issue":"1","key":"2311_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"2311_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"2311_CR18","unstructured":"The Cochrane Collaboration. Review Manager Web (RevMan Web). Version 5.4. The Cochrane Collaboration; 2021."},{"issue":"7414","key":"2311_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"2311_CR20","unstructured":"9.7 Sensitivity analyses [Internet]. [cited 2023 Sep 12];Available from: https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_7_sensitivity_analyses.htm"},{"key":"2311_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129\u201341.","journal-title":"J Clin Epidemiol"},{"key":"2311_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 2 Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142\u201352.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2311_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195\u2013203.","journal-title":"Int J Evid Based Healthc"},{"key":"2311_CR24","unstructured":"Jan J Barendregt & Suhail A Doi."},{"key":"2311_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.wneu.2024.09.048","volume":"193","author":"IC Windlin","year":"2025","unstructured":"Windlin IC, da Costa BBS, Mota Telles JP, et al. The effects of glibenclamide on cognitive performance, quality of life, and emotional aspects among patients with aneurysmal subarachnoid hemorrhage: A randomized controlled trial. World Neurosurg. 2025;193:345\u201352.","journal-title":"World Neurosurg"},{"key":"2311_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101666","volume":"53","author":"J Zhao","year":"2022","unstructured":"Zhao J, Song C, Li D, et al. Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial. EClinicalMedicine. 2022;53: 101666.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2311_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm1390","volume":"12","author":"JM Simard","year":"2006","unstructured":"Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006;12(4):433\u201340.","journal-title":"Nat Med"},{"issue":"2","key":"2311_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/STROKEAHA.108.522409","volume":"40","author":"JM Simard","year":"2009","unstructured":"Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009;40(2):604\u20139.","journal-title":"Stroke"},{"issue":"3","key":"2311_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1161\/STROKEAHA.109.572644","volume":"41","author":"JM Simard","year":"2010","unstructured":"Simard JM, Tsymbalyuk N, Tsymbalyuk O, Ivanova S, Yurovsky V, Gerzanich V. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke. 2010;41(3):531\u20137.","journal-title":"Stroke"},{"issue":"1","key":"2311_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s13054-015-1036-0","volume":"19","author":"H Lantigua","year":"2015","unstructured":"Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and why? Crit Care. 2015;19(1):309.","journal-title":"Crit Care"},{"issue":"5","key":"2311_CR31","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1161\/STROKEAHA.122.040072","volume":"54","author":"DC Lauzier","year":"2023","unstructured":"Lauzier DC, Jayaraman K, Yuan JY, et al. Early brain injury after subarachnoid hemorrhage: incidence and mechanisms. Stroke. 2023;54(5):1426\u201340.","journal-title":"Stroke"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-025-02311-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T22:51:13Z","timestamp":1764111073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-025-02311-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1007\/s12028-025-02311-3","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}